Natco's total revenues de-grew by 26% YoY and 56% QoQ to Rs.355cr in Q3FY21 with de-growth seen across geographies. The formulation exports (46% of revenues) de-grew by 13% YoY, while domestic formulations (27% of revenues), de-grew by 37%. The formulation exports were impacted by the lower sales of Tamiflu in the U.S on the back of weak flu season while Brazil and Canada also saw lower revenues. The market share for Copaxone as well as other formulations remains stable. The company stated that the approval for the...